MERIDIAN BIOSCIENCE, INC. Form 8-K: Current report
Filings on SEC EDGAR, newest first; amendments sit with their base form. Values are as filed.
- 2021-12-02: Form 8-K; Period of report 2021-11-29; Description 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; 8.01 Other Events; Details 5.02.
- 2021-11-12: Form 8-K; Period of report 2021-11-12; Description 2.02 Results of Operations and Financial Condition; 7.01 Regulation FD Disclosure; Details 2.02.
- 2021-11-10: Form 8-K; Period of report 2021-11-10; Description 7.01 Regulation FD Disclosure; Details 7.01.
- 2021-10-29: Form 8-K; Period of report 2021-10-25; Description 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant; Details 2.03.
| Filed | Form | Period of report | Description | Details | Document |
|---|---|---|---|---|---|
| 2021-12-02 | 8-K | 2021-11-29 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; 8.01 Other Events | 5.02 On November 29, 2021, Meridian Bioscience, Inc.’s (the “Company”) Executive Vice President, Chief Financial Officer and Secretary, Bryan T. Baldasare, notified the Company of his intention to retire. 8.01 On December 2, 2021, the Company issued a press release regarding Mr. Baldasare’s retirement and Ms. Smith’s promotion as described above under Item 5.02 of this Current Report on Form 8-K. A copy of the press release is attached hereto as Exhibit 99.1 for reference. | d242694d8k.htm |
| 2021-11-12 | 8-K | 2021-11-12 | 2.02 Results of Operations and Financial Condition; 7.01 Regulation FD Disclosure | 2.02 On November 12, 2021, Meridian Bioscience, Inc. (“Meridian” or the “Company”) issued a press release announcing results for the fourth fiscal quarter and full fiscal year ended September 30, 2021. 7.01 On November 12, 2021, Meridian is hosting a conference call for the benefit of its investors to discuss the results set forth in the press release announcing results for the fourth fiscal quarter and full fiscal year ended September 30, 2021 and other business and financial highlights. | d43948d8k.htm |
| 2021-11-10 | 8-K | 2021-11-10 | 7.01 Regulation FD Disclosure | 7.01 On November 10, 2021, Meridian Bioscience, Inc. (the “Company”) issued a press release announcing it has received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) for the Company’s SARS-CoV-2 molecular diagnostic test on the Revogene® platform. | d232350d8k.htm |
| 2021-10-29 | 8-K | 2021-10-25 | 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant | 2.03 Effective October 25, 2021, Meridian Bioscience, Inc. (“Meridian” or the “Company”) entered into a $200,000,000 Revolving Credit Facility (“Credit Facility”) under the Amended and Restated Credit Agreement by and among Meridian, the Guarantors party thereto, the lenders party thereto, PNC Bank, National Association, as Administrative Agent, PNC Capital Markets LLC, as Joint Lead Arranger and Sole Bookrunner, and Fifth Third Bank, National Association, as Joint Lead Arranger and Syndication Agent (the “Amended and Restated Credit Agreement”). | d213057d8k.htm |
| 2021-09-01 | 8-K | 2021-09-01 | 7.01 Regulation FD Disclosure | 7.01 On September 1, 2021, Meridian Bioscience, Inc. (“Meridian” or the “Company”) issued a press release regarding an expanded product recall for LeadCare® II, LeadCare Plus® and LeadCare Ultra® Blood Lead Test Kits manufactured and sold by its wholly owned subsidiary, Magellan Diagnostics, Inc. (“Magellan”) A copy of the press release is furnished as Exhibit 99.1 to this report and is incorporated by reference herein. | d183634d8k.htm |
| 2021-08-06 | 8-K | 2021-08-06 | 2.02 Results of Operations and Financial Condition; 7.01 Regulation FD Disclosure | 2.02 On August 6, 2021, Meridian Bioscience, Inc. (“Meridian” or the “Company”) issued a press release announcing results for the third fiscal quarter ended June 30, 2021. 7.01 On August 6, 2021, Meridian is hosting a conference call for the benefit of its investors to discuss the results set forth in the press release announcing results for the third fiscal quarter ended June 30, 2021 and other business and financial highlights. | d194833d8k.htm |
| 2021-08-02 | 8-K | 2021-08-02 | 8.01 Other Events | 8.01 On August 2, 2021, Meridian Bioscience, Inc. issued a press release announcing the closing of the transactions contemplated by its agreement to acquire urea breath test assets from Otsuka America Pharmaceutical Inc. A copy of the press release is attached hereto as Exhibit 99.1 and incorporated herein by reference. | d196313d8k.htm |
| 2021-07-23 | 8-K | 2021-07-23 | 8.01 Other Events | 8.01 On July 23, 2021, Meridian Bioscience, Inc. issued a press release announcing its execution of a definitive agreement to acquire urea breath test assets from Otsuka America Pharmaceutical, Inc. A copy of the press release is attached hereto as Exhibit 99.1 and incorporated herein by reference. | d176623d8k.htm |
| 2021-07-13 | 8-K | 2021-07-13 | 2.02 Results of Operations and Financial Condition | 2.02 On July 13, 2021, Meridian Bioscience, Inc. (“Meridian” or the “Company”) issued a press release announcing preliminary results for the third fiscal quarter ended June 30, 2021. | d199289d8k.htm |
| 2021-06-28 | 8-K | 2021-06-28 | 7.01 Regulation FD Disclosure | 7.01 On June 28, 2021, Meridian Bioscience, Inc. (the “Company”) issued a press release announcing its resubmission of its application for Emergency Use Authorization (EUA) to the U.S. Food and Drug Administration (FDA) for the Company’s SARS-CoV-2 molecular diagnostic test on the Revogene® platform. | d193036d8k.htm |
| 2021-05-07 | 8-K | 2021-05-07 | 2.02 Results of Operations and Financial Condition; 7.01 Regulation FD Disclosure | 2.02 On May 7, 2021, Meridian Bioscience, Inc. (“Meridian” or “the Company”) issued a press release announcing results for the second fiscal quarter ended March 31, 2021. 7.01 On May 7, 2021, Meridian is hosting a conference call for the benefit of its investors to discuss the results set forth in the press release announcing results for the second fiscal quarter ended March 31, 2021 and other business and financial highlights. | d289877d8k.htm |
| 2021-02-23 | 8-K/A | 2021-02-23 | 7.01 Regulation FD Disclosure | 7.01 On the morning of February 23, 2021, Meridian Bioscience, Inc. (“Meridian” or the “Company”) issued a press release providing an update regarding its emergency use authorization request to the U.S. Food and Drug Administration with respect to its Revogene SARS-CoV-2 test (the “Original Release”) and filed a Form 8-K (the “Original Form 8-K”) which furnished as an exhibit a copy of the Original Release. | d117921d8ka.htm |
| 2021-02-23 | 8-K | 2021-02-23 | 7.01 Regulation FD Disclosure | 7.01 On February 23, 2021, Meridian Bioscience, Inc. (“Meridian” or the “Company”) issued a press release regarding its emergency use authorization request to the U.S. Food and Drug Administration with respect to its Revogene SARS-CoV-2 test. | d23318d8k.htm |
| 2021-02-16 | 8-K | 2021-02-16 | 7.01 Regulation FD Disclosure | 7.01 On February 16, 2021, Meridian Bioscience, Inc. (“Meridian” or the “Company”) issued a press release regarding its emergency use authorization application to the U.S. Food and Drug Administration with respect to its Revogene SARS-CoV-2 test. | d58289d8k.htm |
| 2021-02-05 | 8-K | 2021-02-05 | 2.02 Results of Operations and Financial Condition; 7.01 Regulation FD Disclosure | 2.02 On February 5, 2021, Meridian Bioscience, Inc. (“Meridian” or the “Company”) issued a press release announcing results for the first fiscal quarter ended December 31, 2020. 7.01 On February 5, 2021, Meridian is hosting a conference call for the benefit of its investors to discuss the results set forth in the press release announcing results for the first fiscal quarter ended December 31, 2020 and other business and financial highlights. | d119657d8k.htm |
| 2021-01-29 | 8-K | 2021-01-27 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; 5.07 Submission of Matters to a Vote of Security Holders | 5.02 At the January 27, 2021 Annual Meeting (the “Meeting”) of the shareholders of Meridian Bioscience, Inc. (the “Company”), shareholders approved the 2021 Omnibus Award Plan (the “2021 Plan”). 5.07 At the Meeting, shareholders voted on the matters set forth below. | d115640d8k.htm |
| 2021-01-12 | 8-K | 2021-01-12 | 8.01 Other Events | 8.01 On December 16, 2020, Meridian Bioscience, Inc. (the “Company”) filed and mailed a definitive proxy statement (as supplemented by a supplement dated December 30, 2020, the “Proxy Statement”) describing the matters to be voted on at the Company’s annual meeting of shareholders to be held on January 27, 2021 (the “2021 Annual Meeting”), including the approval of the Meridian Bioscience, Inc. 2021 Omnibus Award Plan (the “Plan”), which is attached as Appendix A to the Proxy Statement. | d84658d8k.htm |
| 2021-01-07 | 8-K | 2021-01-07 | 2.02 Results of Operations and Financial Condition | 2.02 On January 7, 2021, Meridian Bioscience, Inc. (“Meridian” or the “Company”) issued a press release announcing preliminary results for the first fiscal quarter ended December 31, 2020. | d236109d8k.htm |